4//SEC Filing
Roberts Christopher D. 4
Accession 0000899243-21-004959
CIK 0001701541other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 5:47 PM ET
Size
8.8 KB
Accession
0000899243-21-004959
Insider Transaction Report
Form 4
Roberts Christopher D.
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2021-02-03$10.86/sh+2,500$27,150→ 5,700 total - Sale
Common Stock
2021-02-03$25.35/sh−2,500$63,375→ 3,200 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-03−2,500→ 171,109 totalExercise: $10.86Exp: 2029-09-08→ Common Stock (2,500 underlying)
Footnotes (2)
- [F1]Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020.
- [F2]25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
Documents
Issuer
Black Diamond Therapeutics, Inc.
CIK 0001701541
Entity typeother
Related Parties
1- filerCIK 0001788368
Filing Metadata
- Form type
- 4
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 5:47 PM ET
- Size
- 8.8 KB